Efficacy of Gene Therapy Is Dependent on Disease Progression in Dystrophic Mice with Mutations in the FKRP Gene

Godfrey, 2011, Dystroglycanopathies: coming into focus, Curr. Opin. Genet. Dev., 21, 278, 10.1016/j.gde.2011.02.001 Aravind, 1999, The fukutin protein family--predicted enzymes modifying cell-surface molecules, Curr. Biol., 9, R836, 10.1016/S0960-9822(00)80039-1 Esapa, 2002, Functional requirements for fukutin-related protein in the Golgi apparatus, Hum. Mol. Genet., 11, 3319, 10.1093/hmg/11.26.3319 Kuchta, 2009, Comprehensive classification of nucleotidyltransferase fold proteins: identification of novel families and their representatives in human, Nucleic Acids Res., 37, 7701, 10.1093/nar/gkp854 Kanagawa, 2016, Identification of a post-translational modification with ribitol-phosphate and its defect in muscular dystrophy, Cell Rep., 14, 2209, 10.1016/j.celrep.2016.02.017 Ibraghimov-Beskrovnaya, 1992, Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix, Nature, 355, 696, 10.1038/355696a0 Nilsson, 2010, Characterization of site-specific O-glycan structures within the mucin-like domain of α-dystroglycan from human skeletal muscle, Glycobiology, 20, 1160, 10.1093/glycob/cwq082 Yoshida-Moriguchi, 2010, O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding, Science, 327, 88, 10.1126/science.1180512 Brockington, 2001, Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin α2 deficiency and abnormal glycosylation of α-dystroglycan, Am. J. Hum. Genet., 69, 1198, 10.1086/324412 Beltran-Valero de Bernabé, 2004, Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome, J. Med. Genet., 41, e61, 10.1136/jmg.2003.013870 Michele, 2002, Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies, Nature, 418, 417, 10.1038/nature00837 Brown, 2004, Abnormalities in α-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies, Am. J. Pathol., 164, 727, 10.1016/S0002-9440(10)63160-4 Poppe, 2003, The phenotype of limb-girdle muscular dystrophy type 2I, Neurology, 60, 1246, 10.1212/01.WNL.0000058902.88181.3D Martin, 2007, Congenital muscular dystrophies involving the O-mannose pathway, Curr. Mol. Med., 7, 417, 10.2174/156652407780831601 Roscioli, 2012, Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of α-dystroglycan, Nat. Genet., 44, 581, 10.1038/ng.2253 Willer, 2012, ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome, Nat. Genet., 44, 575, 10.1038/ng.2252 Fisher, 1997, Recombinant adeno-associated virus for muscle directed gene therapy, Nat. Med., 3, 306, 10.1038/nm0397-306 Daya, 2008, Gene therapy using adeno-associated virus vectors, Clin. Microbiol. Rev., 21, 583, 10.1128/CMR.00008-08 Qiao, 2005, Amelioration of laminin-α2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin, Proc. Natl. Acad. Sci. USA, 102, 11999, 10.1073/pnas.0502137102 Bartoli, 2006, Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A, Mol. Ther., 13, 250, 10.1016/j.ymthe.2005.09.017 Mendell, 2009, Limb-girdle muscular dystrophy type 2D gene therapy restores α-sarcoglycan and associated proteins, Ann. Neurol., 66, 290, 10.1002/ana.21732 Xu, 2013, Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions, Mol. Ther., 21, 1832, 10.1038/mt.2013.156 Qiao, 2014, Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery, Mol. Ther., 22, 1890, 10.1038/mt.2014.141 Vannoy, 2014, Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein, Hum. Gene Ther. Methods, 25, 187, 10.1089/hgtb.2013.151 Chan, 2010, Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies, Hum. Mol. Genet., 19, 3995, 10.1093/hmg/ddq314 Blaeser, 2013, Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes, Hum. Genet., 132, 923, 10.1007/s00439-013-1302-7 Ervasti, 1991, Membrane organization of the dystrophin-glycoprotein complex, Cell, 66, 1121, 10.1016/0092-8674(91)90035-W Zincarelli, 2008, Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection, Mol. Ther., 16, 1073, 10.1038/mt.2008.76 Mingozzi, 2013, Immune responses to AAV vectors: overcoming barriers to successful gene therapy, Blood, 122, 23, 10.1182/blood-2013-01-306647 Salva, 2007, Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle, Mol. Ther., 15, 320, 10.1038/sj.mt.6300027 Beedle, 2007, Fukutin-related protein associates with the sarcolemmal dystrophin-glycoprotein complex, J. Biol. Chem., 282, 16713, 10.1074/jbc.C700061200 Li, 1999, rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy, Gene Ther., 6, 74, 10.1038/sj.gt.3300830 Xiao, 1998, Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus, J. Virol., 72, 2224, 10.1128/JVI.72.3.2224-2232.1998 Snyder, 1996, Production of recombinant adeno-associated viral vectors, 12.1.1 Veldwijk, 2002, Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks, Mol. Ther., 6, 272, 10.1006/mthe.2002.0659 Rohr, 2005, Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles, J. Virol. Methods, 127, 40, 10.1016/j.jviromet.2005.03.006